Revenue momentum & ODM scaling — is Q2 tracking the ₹1,100+ Cr FY27 guidance?
Syrma SGS delivered a 67% revenue surge in Q1 on automotive, exports, and accelerating ODM. Q2 will test whether the momentum holds and margins stay anchored at 10.5–11% guidance.
What to expect: the key metric
Syrma SGS has pivoted from contract manufacturing toward higher-margin ODM (original design & manufacturing) and specialized verticals — automotive, consumer electronics, and medical devices. Q2 will test whether the company can sustain the 67% revenue growth delivered in Q1 while holding the 10.5–11% EBITDA margin guidance. The Street is watching three things: (1) whether ODM momentum (₹270 Cr in Q1, now 17% of revenue) continues to scale toward the ₹1,100–1,200 Cr FY27 target; (2) whether new manufacturing capacity — the Jodhpur MedTech facility, Bengaluru electronics JV with Elemaster, and the Kaga partnership — sustains growth without margin dilution; and (3) export revenue trajectory, guided toward ₹1,500–1,600 Cr for the full year.
~₹1,600–1,700 Cr
Extrapolating Q1 run-rate (₹1,604 Cr) and the FY27 order book of ₹6,770 Cr
~10.5–11%
Company guidance; Q1 ran at 11% (EBITDA ₹177 Cr). Margin sustenance is critical amid factory ramp-up.
~₹300–350 Cr
Extrapolating Q1 run (₹270 Cr); path to FY27 target ₹1,100–1,200 Cr. FY25–FY26 baseline was ~₹90 Cr per quarter.
~₹110–130 Cr
Q1 was ₹106 Cr on 112% YoY growth. Sustaining 20%+ net profit growth YoY would be on-plan.
A strong Q2 print: Revenue at or above ₹1,650 Cr with EBITDA margin holding at 11% or better; PAT ₹125+ Cr; ODM order book at ₹6,500+ Cr with no cancellations flagged; new facility utilization ramping (Jodhpur, Bengaluru). A weak print: Revenue below ₹1,550 Cr; EBITDA margin slip to 10% or below due to unplanned factory costs; ODM growth stalling (revenue ~₹280 Cr or less); capex overruns flagged; order book softening or customer pushouts into Q3.
On track?
Syrma's trajectory is strong. Q1 delivered 67% revenue growth and 112% profit growth, well ahead of pre-COVID comparables and significantly above the BSE small-cap median (5–8% growth). The company is confident of exceeding full-year guidance, per management commentary in late July. Q2 is the proof point: if the company maintains >60% YoY revenue growth and margin discipline, it will be on track to deliver FY27 revenues in the ₹6,400–6,800 Cr range (implied from quarterly run-rate and the ₹6,770 Cr order book). The key risk is whether new manufacturing capacity ramps without cost overruns; all three projects (Jodhpur, Bengaluru JV, Kaga partnership) are at early operational stages.
What the Street says
Since last quarter
Oct 22
Oct 30 board meeting to approve Q2 FY27 unaudited results (standalone & consolidated)
Board Meeting Intimation
Sep 28
Insider trading window closed for designated persons, routine pre-result compliance
Trading Window Closure
Sep 22
Syrma Johri MedTech inaugurated 120,000+ sq ft Medical Plastics & Precision Molding facility in Jodhpur, Rajasthan. Supports MedTech scaling.
Capex — Jodhpur Facility
Sep 10
Syrma SGS JV renamed to Syrma SGS Elemaster Private Limited post-transaction completion and share allotment
JV Rebranding
Sep 02
Syrma SGS Elemaster (JV with Elemaster S.P.A) inaugurated state-of-the-art high-reliability electronics manufacturing facility in Bengaluru
Capex — Bengaluru Electronics JV
Aug 25
Sandeep Tandon re-appointed Executive Chairman (term effective Oct 1, 2026); Jayesh Doshi appointed Whole-time Director; Jaidit Singh Brar (CEO, appointed June 29) leads operations
Management — Re-appointment & Appointments
Aug 18
New subsidiary Syrma Kaga Electronics Private Limited incorporated for electronics manufacturing JV with Kaga Electronics India Private Limited
Capex — Kaga JV Incorporation
Aug 03
22nd AGM held; ₹1.50 per share dividend proposed (total payout basis FY26 profits)
AGM & Dividend
Oct 01
Franklin Templeton sold 110,190 shares (0.057% of capital). Routine fund rebalancing; no major promoter/insider activity.
Shareholding — FII Sell
Operational highlights: Three new manufacturing facilities came online in Q2 (Jodhpur MedTech, Bengaluru electronics, Kaga partnership). All are early-stage capex; ramp costs may pressure margins near-term. Management remains confident of exceeding FY27 guidance. Corporate governance: No unusual insider trading; management continuity maintained (CEO in post, Chairman re-appointed). Franklin Templeton's small exit is routine portfolio rebalancing, not a bearish signal. Risk flagged: Capex cycle underway; watch for any guidance revisions on margin sustenance or delivery timelines on new facilities.
What to watch on result day
1 · Revenue & growth trajectory
Is Q2 revenue at or above ₹1,600 Cr? Is YoY growth still >60%? Any softness in order book inflow or customer pushouts into Q3?
2 · EBITDA margin sustenance
Does Q2 EBITDA margin hold at 10.5–11% guidance, or has new factory ramp inflated costs? Margin is the swing factor for credibility.
3 · ODM business & order book
What is Q2 ODM revenue? Is the path to FY27 target (₹1,100–1,200 Cr) intact? Any customer concentration risk or cancellations?
4 · New facility utilization & capex spend
How much capex was deployed in Q2? Are Jodhpur, Bengaluru, and Kaga facilities ramping to plan? Any timeline slips or cost overruns?
5 · FY27 guidance reaffirmation
Management has said it is confident of exceeding FY27 guidance. Will they raise numbers, maintain, or flag any near-term caution (e.g., export demand softness, semiconductor lead-times)?
Syrma SGS is at an inflection — shifting from legacy contract manufacturing into ODM, automotive, and medical device design. Q1 validated the thesis: 67% revenue growth, doubling of ODM contribution, and 112% PAT surge. Q2 is the acid test. The company must prove that new manufacturing capacity ramps without margin erosion, and that the ₹6,770 Cr order book sustains momentum into Q3 and H2. Street consensus remains bullish (Buy, ₹1,457 target), but execution risk is real: capex cycle, customer concentration in ODM, and automotive exposure to global EV headwinds. Watch revenue and margin discipline. On-plan print (₹1,600+ Cr revenue, 10.5–11% margin) should re-rate the stock; a miss would trigger a correction.
Informational and educational content only. Not investment advice.